美国食品药品监督管理局周一表示，美国卫生官员正在推进首个由政府资助的迷幻药伊博格碱临床试验，用于治疗阿片类药物成瘾和创伤后应激障碍，同时就研究的安全规则征求公众意见。
US health officials are advancing the first government-funded clinical trials of the psychedelic drug ibogaine to treat opioid addiction and post-traumatic stress disorder, the FDA said on Monday, as it sought public feedback on safety rules for the studies.